<qa>  What is the primary outcome of mycophenolate mofetil monotherapy?Eligible patients will be randomized to receive either mycophenolate mofetil monotherapy MMF; CNI discontinued, or mycophenolate mofetil and half their baseline dose of calcineurin inhibitor MMF; CNI decreased. The primary outcome is biopsy proven rejection and the secondary outcomes include patient and graft survival, adverse events, hepatic profile, blood pressure, renal function, diabetes, and lipid profile. Additionally, mycophenolic acid concentrations will be measured; a mycophenolate mofetil monotherapy trial provides unique opportunity to study the implications of such monitoring. Patients will be followed for 12 months; there will be 16 visits during the trial. 